

IMMUNOTHERAPY CEO JEFF GALVIN JOINS THE BOARD OF DIRECTORS OF THE CANCER SUPPORT COMMUNITY

ROCKVILLE, MD, UNITED STATES, September 6, 2018 /EINPresswire.com/ -- Jeff Galvin, a former Silicon Valley CEO, and now a leader in the field of gene and cell therapy to cure cancer and other human diseases, has joined the Board of Directors of the [Cancer Support Community](#) (CSC). Galvin's biotech company, [American Gene Technologies International Inc.](#) (AGT), is striving to create the next big revolution in cancer therapies with Gamma Delta T Cell immunotherapy, which uses a method to stimulate the immune system to kill solid cancer tumors. AGT has four patents on this method with the mission to cure epithelial cancers ([10,036,040](#), [10,023,880](#), [9,914,938](#), [9,834,790](#)).

Galvin earned his BA degree in Economics from Harvard in 1981. He has more than 30 years of business and entrepreneurial experience, including founder or executive positions at a variety of Silicon Valley startups. Several of his companies were taken public and/or sold to public companies.

"Jeff Galvin is leveraging his passion, drive, and successful business experience and to revolutionize treatment for cancer and other vexing medical problems facing patients today. It is a privilege to have Jeff join our Board and share his expertise to strengthen our organization," said Jill Durovsik, Chair of CSC's Board of Directors.

CSC is the largest professionally led non-profit network of cancer support world-wide with a network of 175 locations, providing \$50 million in free support services to patients and families. CSC's mission is to ensure that "people impacted by cancer are



American Gene Technologies™
Where Creativity Cures™



**CANCER SUPPORT
COMMUNITY.**



Jeff Galvin, CEO of American Gene Technologies

empowered by knowledge, strengthened by action, and sustained by community.”

Kim Thiboldeaux, CEO of CSC, author, and blogger, shared, “We recently completed a study at CSC which found a pressing need among patients and caregivers for information to help them navigate the new world of immunotherapy. We are thrilled to have the leadership and expertise of Jeff Galvin on the Board to support CSC as we empower and educate patients about the many new treatment options available to them.”

Jeff Galvin added, “I’m honored to join CSC’s Board of Directors. It is a privilege to play a role in this important organization, helping to ensure that people impacted by cancer have access to support and knowledge that empowers them to act effectively in making their treatment plans and decisions.”

About American Gene Technologies (AGT):

AGT is an emerging gene and cell therapeutics company with a proprietary lentiviral platform capable of broad applications including: large and orphan indications, infectious disease, immune-oncology, and monogenic disorders. AGT expects to take its patented, lead candidate for an HIV Cure into the clinic in 2019. It has pioneered a novel immuno-oncology approach of stimulating gamma-delta ($\gamma\delta$) T cells to attack a variety of cancers. Four key patents in AGT’s novel immuno-oncology approach have been granted. AGT has a diverse portfolio of patent filings surrounding key tools and components in viral vectors, gene therapy, and regenerative medicine.

Website - <https://bit.ly/2PJPBXI>

LinkedIn - <https://www.linkedin.com/company/american-gene-technologies-international-inc/>

Twitter - @americangene, <https://twitter.com/americangene>

Facebook - @amerigene, <https://www.facebook.com/amerigene/>

Instagram - @americangenetechnologies,

<https://www.instagram.com/americangenetechnologies/>

American Gene Technologies Contact:

C. Neil Lyons, Chief Financial Officer

Phone: (301) 337-2269

Email: info@americangene.com

Sasha Whitaker

American Gene Technologies

(301) 337-2100

[email us here](mailto:info@americangene.com)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.